drugset / Trial / NCT07127874
A Study of PHN-012 in Patients With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Timeline
- Start
- 2025-09-23
- Primary completion
- 2027-09
- Completion
- 2028-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PHN-012 | Unknown | — | Intravenous |